Biolife Solutions Announces Preliminary Unaudited Revenue Results for Fourth Quarter and Full Year 2023
January 08, 2024 at 06:45 pm IST
Share
BioLife Solutions announced Preliminary Unaudited Revenue results for Fourth Quarter and Full Year 2023. For the quarter, the company reported revenue for the fourth quarter of 2023 was $32.7 million, a decrease of 26% from $44.3 million for the fourth quarter of 2022.
For the year, the company reported revenue for the full year 2023 was $143.3 million, a decrease of 11% from $161.8 million for 2022.
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.